



REFERENCES

- Adamis, A.P. ; Miller, J.W. ; Bernal, M.T.; et al. (1999):** Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. *Am J Ophthalmol*; 118: 445 -50.
- Ahmad, S.(1997):** Angiotensin receptor antagonists delay nitric oxide-deficient stroke in stroke prone rats. *Eur J Pharmacol*; 333: 39-45.
- Allen, A.M.; Zhuo, J. and Mendelsohn, F. (2000):** Localization and function of angiotensin AT₁ receptors. *Am J Hypertens*; 13: 31S-38S.
- Amerena, J.; Pappas, S.; Ouellet, J.P.; Williams, L. and Shaughnessy, D. (2002):** ABPM comparison of the antihypertensive profiles of telmisartan and enalapril in patients with mild-to- moderate essential hypertension. *J Int Med Res*; 30(6): 543-552.
- Araki, K.; Masaki, T.; Katsuragi, I.; Tanaka, K.; Kakuma, T. and Yoshimatsu, H. (2006):** Telmisartan Prevents Obesity and Increases the Expression of Uncoupling Protein 1 in Diet-Induced Obese Mice. *Hypertension*; 48:51.
- Arner, P. (1997):** Regional adiposity in man. *J Endocrinol*;155, 191– 92.
- Asmar, R; Gosse, P; Topouchain, J., et al. (2002):** Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. *J. Renin Angiotensin Aldosterone Syst*; 3:176-80.
- Avramoglu, R.K.; Qiu, W. and Adeli, K.(2003) :**Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation



of hepatic and intestinal lipoprotein secretion. *Front Biosci.*, 8:d464–476.

Babaev, V.R.; Yancey, P.G.; Ryzhov, S.V.; et al., (2005): Linton MF conditional knockout of macrophage (PPAR)- γ increase atherosclerosis in C57BL/6 and LDL receptor deficient mice. *Arterioscler Thromb Vasc Biol*; 25: 1647-53.

Bakris, G. (2002): Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. *J Clin Hypertens*; (4 Suppl 1): 26-31.

Ball, S.G. (2003): Benefits of blood pressure reduction in diabetic patients. *J Hypertens*; 21: S31-6.

Barnett, A.H.(2005): (Preventing renal complications in diabetic patients): The Diabetics Exposed to Telmisartan And enalapril (DETAIL) study. *Acta Diabetol*; 42(Suppl 1): S42-9.

Basciano, H.; Federico, L. and Adeli, K.; (2005): Fructose, insulin resistance, and metabolic dyslipidemia. *Nutr Metab (Lond)*;2: 5.

Baum, M. (1998): Insulin stimulates volume absorption in the rabbit proximal convoluted tubule. *J. Clin Invest*; 79 : 1104 -9.

Bays, H. and Stein, E.A. (2003): Pharmacotherapy for dyslipidaemia current therapies and future agents. *Expert Opin Pharmacother*; 4, 1901–1938.

Bays, H.; Mandarino, L.; and DeFronzo, R.A.(2004):Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator- activated



receptor agonists provide a rational therapeutic approach. *J. Clin Endocrinol Metab*; 89, 463–478.

Becker, J.; Delayre-Orthez, C.; Frossard, N. and Pons, F.(2006): Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases. *Fundam Clin Pharmacol*; 20(5):429-47.

Beiger, W.P.; Michel, G.; Barwich, D. and Writh, A. (1998): Diminished insulin receptors on monocytes and erythrocytes in hypertriglyceridemia. *Metabolism*; 33 : 982 – 7.

Belvisi, M.G.; Hele, D.J.and Birrell, M.A.(2004): New advances and potential therapies for the treatment of asthma; 18(4):211-23.

Benson, S.C; Pershadsingh, H.A; Ho, C.I., et al. (2004): Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma- modulating activity. *Hypertension*; 43:993-1002.

Berg, A.H.; Combs, T.P.; Du, X.; Brownlee, M. and Scherer, P.E. (2001): The adipocyte – secreted protein Acrp 30 enhances hepatic insulin action. *Nat Med*; 7 : 947 – 953.

Berger, J.P.; Akiyama, T.E. and Meinke, P.T.(2005): PPARs: therapeutic targets for metabolic disease. *Trends Pharmacol Sci*; 26 (5): 244-51.

Berk, B.C. and Corson, M.A. (1997): Angiotensin II signal transduction in vascular smooth muscle. Role of tyrosine kinases. *Circ Res*; 80:607–616.



- Berry, C.; Touyz, R.M.; Dominiczak, F.; Webb, R.C. and Johns, D.G. (2001):** Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide Am J Heart Circ Physiol; 281: H2337-H2365.
- Blessing, E.; Preusch, M.; Kranzhofer, R. et al.(2007):** Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis; 199(2) :295-303.
- Boden, G. (2003) :**Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism; 52: 753–759.
- Brasier, A.R.; Recinos A.; Eledirsi, M. S.(2002):** Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol; 22: 1257- 66.
- Brenner, B.M.; Cooper, M.E.; Zeeuw, D., et al., (2001):** Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med; 345: 861-9.
- Bruemmer, D.; Berger, J.P.; Liu, J., et al., (2003) :**A non thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol; 466: 225–234.
- Burgess, E.D. and Buckley, S. (2000):** Long term effect of telmisartan on sodium excretion in hypertensive patients. Can J Cardiol; 16 Suppl F: 106F.



- Burn, J.H. (1952):** In practical pharmacology "Blackwell scientific publication Ltd., Oxford; P.8.
- Burnier, M. (2001):** Angiotensin II type I Receptor Blockers. Circulation; 103 (6):904-912.
- Burnier, M. and Maillard, M. (2001):** The comparative pharmacology of angiotensin II receptor antagonists. Blood Press; 10 Suppl 1:6-11.
- Caggiula, AW. and Mustad, VA. (1997):** Effects of dietary fat and fatty acids on coronary artery disease risk and total and lipoprotein cholesterol concentrations: epidemiology studies. Am J Clin Nutr; 65:1597S– 1610S.
- Cangiano, J. L.; Carmen, R. S. and Mauuel, M. M. (1978):** Effect of antihypertensive treatment on systolic blood pressure and renin in hypertensive rats: Hypertension; 12: 102-115.
- Carey, R.M.; Wang, Z.Q. and Siragy, H. (2000):** Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function . Hypertension; 35 :155-163.
- Chinetti, G.; Lestavel, S.; Bocher, V.; et al., (2001):** PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nat Med; 7: 53–58.
- Chiu, A.I; Mc Call, D.E. and Price W.A. (1991):** In vitro pharmacology of Dup 753. Am. J. Hypertens; 4: 68-75.
- Chyu, K.; Babbidge, S.M.; Zhao, X.; Dandillaya, R.; et al. (2004):** Differential Effects of Green Tea–Derived Catechin on



Developing Versus Established Atherosclerosis in Apolipoprotein E- Null Mice. *Circulation*; 109:2448-2453.

Cogan, D. G.; Toussaint, D. and Kuwaba, T. (1991): Retinal vascular patterns. IV. Diabetic retinopathy. *Arch Ophthalmo*; 66: 366-378.

Crapo, P.A.; Kolterman, O.G. and Henry, R.P. (1986): Metabolic consequence of two – week fructose feeding in diabetic subjects. *Diabetes Care*; 9 : 111 – 9.

Criscione, L.; De Gaspro, M.; Busehlmayez, P.; White bread, S.; Pamjoue, H.P. and Wood, J.M. (1992): Pharmacological profile of C.G.P. 48933, a novel non peptied antagonist of AT₁ receptor *J Hypertens*; (G.B.) 10, suppl. 4, 196.

Cupisti, A.; Rizza, G.M.; D'Alessandro, C.; Morelli, E. and Barsotti, G. (2003): Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. *Biomed. Pharmacother*; 57 (3-4): 169-72.

Cusi, K; Maezono, K; A.and Pedrinelli, R.; (2000): Insulin resistance differentially affects the P13-kinase- and MAP kinase- mediated signaling in human muscle. *J Clin Invest*; 105:311-20.

De Gasparo, M.; Catt, K.J.; Inagami, T.; Wright, J.W. and Unger, T. (2000): International Union of Pharmacology XIII: the angiotensin II receptors. *Pharmacol Rev*; 52: 472.

De Gasparo, M.; Husain, A.; Alexander, W.; Catt, K.J.; Chiu, A.T.; et al., (2000): Proposed update of angiotensin receptor nomenclature. *Hypertension*; 25:924–927.



- Derosa, G.; Cicero, A.F. Graziadei, L.; et al.(2006):** Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone. *Hypertens Res*; 29:849-856.
- Derosa, G; Ragonesi, P.D.; Mugellini, A; Ciccarelli, L. and Fogari, R. (2004):** Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo. *Hypertens Res*; 27(7):457-64
- Dhalla, N.S.; Xu, Y.J.; Sheu, S.S.; Tappia, P.S. and Panagia, V. (1997):** Phosphatidic acid: A potential signal transducer for cardiac hypertrophy. *J Mol Cell Cardiol*; 29:2865– 2871.
- Dulin, N.O.; Alexander, L.D.; Harrwalkar, S.; Falck, J.R. and Douglas, J.G. (1998):** Phospholipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II. *Acad Sci USA*; 95:8098–8102.
- Dunselman, P.H. (2001):** Replacement of Angiotensin Converting Enzyme Inhibition (REPLACE) Investigators: Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan. *Hypertens*;105, 1135–1143.
- Dury, R.A. and Wallington, E.A.(1967):** Garletons histological Technique, 4th ed. Oxford university press, Oxford; p.129.
- Dwyer, J. (1995):** Overview: dietary approaches for reducing cardiovascular disease risks. *J Nutr*; 125:656–665.



- Ebner, T.; Prox, A. and Wachsmuth, H. (1999):** Stability of telmisartan and chemical structure. *Journal of Human Hypertension*; 13(suppl 3): 12.
- Efendic, S.; Karlander, S. and Vranic, M.(1988):** Mild type II diabetes markedly increases glucose cycling in the post absorptive state and during glucose infusion irrespective of obesity . *J Clin Invest*; 81: 1953-1961.
- Elkayam, A.; Mirelman, D.; Peleg, E.; Wilchek, M.; Miron, T.; Rabinkov, A.; Sadetzki, S. and Rosenthal, T.(2001):** The effects of fructose-induced hyperinsulinemic hyperlipidemic hypertensive rats. *Am J Hypertens*.;14(4 Pt 1):377-81
- Erbe, D.V.; Gartrell, K.; Zhang, Y.L. et al(2006):** Molecular activation of PPAR-gamma by angiotensin II type 1-receptor antagonists. *Vascul Pharmacol*. 45:154-162.
- Ernsberger, P. and Koletsky, R. J. (2007) :** Metabolic action of angiotensin receptor antagonist : PPAR – gamma agonist action or a class effect. *Curr Opin Pharmacol*; 7 (2): 140 -5.
- Ferrannin, E.; Buzzigole, G.; Bonadonna, R., et al.,(1997):** Insulin Resistance in essential hypertension. *N Engl J Med*; 317 : 335 – 357.
- Fliser, D.; Buchholz, K. and Haller, H. (2004) :** Anti inflammatory effects of angiotensin II subtype I receptor blockade in hypertensive patients with microinflammation. *Circulation*; 110: 1103-7.



- Folli, F.; Saad, M.J. ; Velloso, L.(1999):** Crosstalk between insulin and angiotensin II signaling systems. *Exp Clin Endocrinol Diabetes*;107:133-9.
- Fossati, P. (1982):** Enzymatic colorimetric determination of serum triglycerides. *Clin Chem*; 28:2077.
- Francischetti, E.A; Celoria , B. M. ; Francischetti , A. and Genelhu, V.A.(2008):** Treatment of hypertension in individuals with the cardiometabolic syndrome : role of an angiotensin II receptor blocker , telmisartan . *Expert Rev cardiovasc Ther*; 6 (3): 289 - 303.
- Freytag, F.; Schelling, A.; Meinicke, T.; Deichsel, G. (2001):** Comparison of 36-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. *Clin Ther*; 23(1): 108-123.
- Friedewald , W .T .et al .,(1972):** *Clin. Chem.*, 18: 499 -512 .
- Fujimoto, M. ; Masuzaki, H. ; Tanaka, T. ; et al. (2004):** An angiotensin II AT₁ receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3L-1 adipocytes. *FEBS Lett.* 576: 492-7.
- Furchgott, R.F. and Bhadrakom, S. (1953):** Reaction of strips of rabbit aorta to epinephrine Isopropyl artenol, sodium nitrate, and other drugs. *J. Pharmacol. Exp. Ther.* 106: 129-143.
- Furuhashi, M.; Ura, N.; Higashiura, K., et al. (2003):** Blockade of the Renin- Angiotensin System Increases Adiponectin



Concentrations in Patients with Essential Hypertension. Hypertension. 42:76-81.

Garcha, R.S.; Sever, P.S. and Hughes, A.D. (1999): Action of AT₁ receptor antagonist on angiotensin II induced tone in human isolated subcutaneous resistance arteries Br J Pharmacol. 127: 1876-1882.

Gavras, H.; Brunner, H.R.; Laragh, J.H.; Vauhon, E.D.; Koss, M., et al., (1975): Malignant hypertension resulting from DOCA and salt excess. Circ Res; 36 : 300 – 309.

Gerard D'Angelo; David M.; Pollock; David W. Stepp(2005): Fructose Feeding Increases Insulin Resistance but Not Blood Pressure in Sprague-Dawley Rats. Hypertension; 46 : 806.

Giles, T. D. (2007) : A perspective on telmisartan and cardiovascular risk Rev Cardiovasc Med; 8 (3) : 154- 9.

Glass, C.K. and Witzum, J.L. (2001): Activation of receptor for advanced glycation end product :a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis .Circ Res;84:97.

Goebal , M.; Clemenz , M. Stael, B.; Unger, T.; Kintscher , U . and Gust , R, (2009): Characterization of New PPAR gamma Agonist :Analysis of Telmisartan structural Components. Chem Med Chem, 5: 102-107.

Gohlke, P.; Pees, C. and Unger, T. (1998): AT₂ receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-depenedent mechanism. Hypertension; 31:349–355.



- Gohlke, P.; Weiss, S.; Jansen, A.; Wienen, W.; Stangier, J.; Rascher, W.; Culman, J. and Unger, T. (2001):** AT₁ receptor antagonist telmisartan administered peripherally inhibits central response to angiotensin II in conscious rats. *J. Pharmacol Exp Ther*; 298(1): 62- 70.
- Goya, K.; Goya, K.; Sumitani, S.; et al.,(2004):** Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthesis expression in vascular endothelial cells. *Arterioscler Thromb Vasc Biol*; 24: 658–663.
- Griendling, K; Sorescu, D; Ushio- Fukai, M.(2000):** Role in cardiovascular biology and disease. *Circ Res*; 86:494-501.
- Griendling, K.; Tsuda, T.; Berk, B.C. and Alexander, R.W. (1989):** Angiotensin II stimulation of vascular smooth muscle. *J Cardiovasc Pharmacol*; 14 (Suppl 6):S27–S33.
- Gross, F. (1950):** The regulation of aldosterone secretion by the renin angiotensin system under various conditions. *Acta Endocrine (Copenh)*, (Suppl 1) 124 :141.
- Grothusen, C.; Bley, S.; Selle, T., et al. (2005):** Combined effects of HMG-CO- reductase inhibition and renin- angiotensin system blockade on experimental atherosclerosis. *Atherosclerosis*; 182:57-69.
- Hammes, H.P.; Lin, J.; Renner, O., et al., (2002):** Pericytes and the pathogenesis of diabetic retinopathy. *Diabetes*; 51: 3107-12.



- Hansen, J.L.; Servant, G.; Baranski, T.J.; Haunso, S. and Sheikh, S.P. (2000):** Functional reconstitution of the angiotensin II type 2 receptor and GI activation. *Circ. Res*; 87:753-759.
- Hayek, T.; Attias, J.; Colman, R.; et al.(2002):** The angiotensin – converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist ,losartan , inhibit LDL oxidation and attenuate atherosclerosis independent mice. *Cardiovasc Res*; 44:579-87.
- Hegele, R.A. Fujita, T.; Iiri, T.; et al. (2002):** PPARG F388L, a trans activation-deficient mutant, in familial partial lipodystrophy. *Diabetes*; 51: 3586–3590.
- Hernandez, H.; McGill, J.B.; Reilly, P.A. (2002):**Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. *Clin Cardiol*; 24: 66-72.
- Heuer, H.J.; Dilger, C.; Michael- Hepp, J. et al., (1998):** Influence of repeated oral doses of telmisartan on the clinical pharmacology of glibenclamide in healthy subjects [abstract no. 38]. *Eur J Clin Pharmacol*; 54(6): A 12.
- Higaki, J.; Baba, S.; Katsuya, T.; et al. (2000):** Deletion Allele of Angiotensin Converting Enzyme Gene Increase Risk of Essential Hypertension in Japancesse Men. The Suita Study. *Circulation*; 101:2060-5.
- Hill, B.A. (1971):** Principles of medical stastics 9th ed. London:, 147-283.



- Hjorth, S.A.; Schambye, H.T.; Greenlee, W.J. and Schwartz, T.W.(1994):** Identification of peptide binding residues in the extracellular domains of the AT₁ receptor. *J Biol Chem*; 269:30953-30959.
- Holmgren, P.R. and Brown, A.C. (1993):** Serum cholesterol levels of nondiabetic and streptozotocin diabetic rats fed a high cholesterol diet. *Artery*; 20:337–345.
- Honda , A. ; Matssuura, k. ; Fukushima , N. ;Tsurumi , Y. Kasanuki , H, and Hagiwara , N. (2008):** Telmisartan induces proliferation of human endothelial progenitor cells via PPAR gamma – dependent PI3 K/ AKT pathway. *Atherosclerosis*; 205(2):376-84.
- Horvath, C.M. and Darnell, J.E. (1997):** Recent developments in the study of signal transduction to the nucleus. *Curr Opin Cell Biol*; 9:233–239.
- Hozumi, T.; Yoshida, M.; Ishida, Y.; Mimoto, H.; Sawa, J.; Doi, K.; and Kazumi, T. (1995):**Long term effects of dietary fiber supplementation on serum glucose and lipoprotein levels in diabetic rats fed a high cholesterol diet. *Endocrinol; J* 42: 187–192.
- Hsueh, W.A. and Bruemmer, D. (2004) :**Peroxisome proliferators activated receptor gamma: implications for cardiovascular disease. *Hypertension*; 43: 297–305.
- Hwang, I.S.; Ho, H.; Hoffman, B.B. and Reaven, G.M. (1999):** Fructose induced insulin resistance & hypertension in rats. *Hypertension Dallas*; 10 : 512 -6.



- Imayama, I.; Ichiki, T.; Inanaga, K.; et al. (2006):** Telmisartan down-regulate angiotensin II type I through activation of (PPAR)- γ Cardiovasc Res;72 :184-90.
- Inagami, T. (1995):** Recent progress in molecular and cell biological studies of angiotensin receptors. Curr Opin Nephrol Hypertens; 4:47-54.
- Ingino, C.; Farsang, C.; Lauecvicius, A. and Bergovec, M. (2003):** An open- label study investigating the efficacy and safety of 12-96 weeks of telmisartan treatment in patients with hypertension. J Int Med Res; 31(6): 561-74.
- Ishihata, A. and Endoh, M. (1993):** Pharmacological characteristics of the positive inotropic effect of angiotensin II in the rabbit ventricular myocardium. Br J Pharmacol; 108 (4): 999-1005.
- Israelian-Konaraki, Z. and Reaven, P.D. (2005):** Peroxisome proliferator- activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology;103: 1–9.
- Israili, Z. H. (2000) :** Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension . J Hum Hypertens ; 14 Suppl 1: S73-86.
- Ivanova, O.V.; Fomicheva, O.A.; Sergakova, L.M.; Chernova, N.A.; Rogoza, A.N. and Karpov, I.U.A. (2002):** Angiotensin II Receptor Blocker Telmisartan: Effect on 24- Hour Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Hypertension. Kardiologiya; 42 (2): 45-9.



- Ivanova , I.; Shchepin, V.A .and Akulin ,V.N.(1986)** : Therapeutic effect of lipids from the Far Eastern Sardine in experimental hypercholesterolemia in rats. Vopr Pitan; 4 : 48-50.
- Iwamoto, K.; Chein, C. and Kato, L. (1987):** Effects of urethane anesthesia and age on organ blood flow in rats measured by hydrogen gas clearance method. J. Pharmacobiodyn; 10 (6): 280.
- Izumi, H.; Nakai, T; and Kano, S. et al., (1996):** Effects of BIBR- 2177, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs. Coronary Artery Disease; 7:775-779.
- Kai, H.; Griendling, K.K.; Lassegue, B.; Ollerenshaw, J.D.; Runge, M.S. and Alexander, R.W. (1994):** Agonist-induced phosphorylation of the vascular type 1 angiotensin II receptor. Hypertension; 24:523–527.
- Kalus, J.S. and White, C.M. (2002):** Amlodipine versus Angiotensin-receptor blockers for non hypertension indications. Ann. Pharmacother; 36 (11): 1759-66.
- Kamari, Y.; Harari, A.; Shaish, A.; Peleg, E.; Sharabi, Y.; Harats, D. and Grossman, E.(2008):** Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats. Hypertens Res; 31(1) :135-40
- Karlocai, K. (2003):** Effects of angiotensin receptor inhibitors on cardiovascular endpoints- current and future evidence. Orv. Hetil; 144 (Suppl I): 901-3.



- Khamaisi, M.; Wexler, I.D.; Skrha, J.; Strojek, K.; Raz, I.; and Milicevic, Z. (2003):** Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities. *Isr Med Assoc J*; 5: 801-6.
- Kintscher, U.; Goetze, S.; Wakino, S.; Kim, S.; Nagpal, S.; et al., (2005):** Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein- 1-directed migration of monocytes. *Eur J Pharmacol*; 401: 259–270.
- Koh, E.T.; Mueller, J.; Osilesi, O.; Knehans, A. and Resier, S. (1985):** Effect of fructose feeding on lipid parameters in obese & lean, diabetic & nondiabetic Zucker rats. *J. Nutr*; 115 : 1274 – 84.
- Komiya, N.; Hirose, H.; Kawabe, H. and Itoh, H. (2008):** Effects of telmisartan therapy on metabolic profiles and serum high molecular weight(HMW)-Adiponectin level in Japanese male hypertensive subjects with abdominal obesity. *J Atheroscler Thromb*; 16(2):137-42.
- Kreiger, D.R. and Landsberg, L. (1988):** Mechanisms in obesity related hypertension : Role of insulin & catecholamines. *Am J Hypertension*; 1 : 84 – 90.
- Kurtz, T.W.(2005):**Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor –gamma activator. *Acta Diabetol*; 42:S9-16.
- Kurtz, T.W. (2006):** New treatment strategies for patient with hypertension and insulin resistance. *Am j Med*; 119 (5 suppl) : S 24-30.



- Lacourciere, Y. (2003):** A new fixed- does combination for added blood pressure control: telmisartan plus hydrochlorothiazide. *J Int Med Res*; 30(4): 366-79.
- Lacourciere, Y.; Lenis, J. and Orchard, R., et al., (1998):** A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. *Blood pressure Monitor*; 3:295-302.
- Laws, D. (2001):** Safety and efficacy of long-term exposure to monotherapy or combination therapy with telmisartan *J RAAS*; 2: 66. [abstract]
- Leevers, S.J.; Vanhaesebroek, B. and Waterfield, M.D. (1999):** Signaling through phosphoinositide 3-kinases: The lipids take centre stage. *Curr Opin Cell Biol*; 11:219– 225.
- Lenz, O.; Schmid, B.; Kilter, H.; La Rosee, K.; Flesch, M.; et al., (1995):** Effects of angiotensin II and angiotensin- converting enzyme inhibitors on human myocardium, *Eur J Pharmacol*; 27 (1): 17-27.
- L'Esperance, F.A.; James W.A. and Judson, P.H. (1999):** The eye and diabetes mellitus. *Diabetes Mellitus Theory and Practice*. New York Elsevier; 661-83.
- Li, A.C.; Brown, K.K.; Silvestre, M.J.; Willson, T.M.; Palinski, W. et al., (2000) :** Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. *J Clin Invest*; 106: 523–531.



- Libby, P.; Libby, P.; Ridker, P.M. and Maseri, A. (2002) :** Inflammation and atherosclerosis. *Circulation*; 105:1135-1143.
- Lijnen, P.J.; Petrov, V.V.; Jackson, K.C. and Fagard, R.H. (2001):** Effect of telmisartan on angiotensin II- mediated collagen gel contraction by adult rat cardiac fibroblasts. *J. Cardiovasc. Pharmacol*; 38 (1): 39-48.
- Lindpaintner, K. and Ganten, R. (1991):** The cardiac renin angiotensin system: an appraisal of present experimental and clinical evidence .*Cir Res*; 68 : 905-921
- Linton, M.F. and Fazio, S. (2000):** Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. *Curr. Atheroscler*; 2: 29–35.
- Littlejohn, T.; Mroczek, W.; Marbury, T.; Vander Maelen, C.P. and Dubiel. R.F. (2000):** A prospective, randomized, open- label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. *Can J Cardiol*; 16 (9): 1123-32.
- Lo, M.W.; Goldberg, J.B. and Lu, H. et al. (1995):** Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and it's active metabolite E-3174 in human. *Clin Pharmacol Ther*; 58 (6): 641-649.
- Lopes –Virella , M.F.; et al . (1977):.** *Clin . chem.*, 23 : 882.
- Luknar, M.; Goncalvesova, E.; Lesny, .P and Fabian, .J.(2010):** Telmisartan and metabolic syndrome after heart transplantation. *Clin Transplant*. 24(1):36-9.



- Maillard. M.; Centeno, C.; Frostell- Karlsson, A.; Brunner, H.R. and Burnier, M. (2001):** Does protein binding modulate the effect of angiotensin II receptor antagonists. JRAAS; 2: S58.
- Maillard, M.; Perregaux. C.; Centeno, C.; Stangier, J.; Wienen, W.; Brunner, H.R. and Burnier, M. (2002):** In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J. Pharmacol Exp Ther; 302 (3): 1089-95.
- Mallion, J.; Siche, J. and Lacourciere, Y. (2000):** ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to- moderate hypertension. J Hum Hypertens; 13(10): 649-50.
- Mandarino, L.J. (1992):** Current hypotheses for the biochemical basis of diabetic retinopathy. Diabetes Care; 15:1892-901.
- Manolis. A.J.; Reid, J.L.; de Zeeuw, D.; et al., (2001):** Angiotensin II receptor antagonist, micardis, in isolated systolic hypertension (ARMIS) study: Efficacy and safety of telmisartan 20, 40, or 80 mg versus hydrochlorothiazide or placebo J. Hypertens, 19 Suppl. 2:S147.
- Marx, N.; Duez, H.; Fruchart, J.C.and Staels, B. (2004):** Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res; 94: 1168–1178.



- Marx, N.; Venema, V.J.; Ling, B.N.; et al. (2003)** :Anti diabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. *Arterioscler Thromb Vasc Biol*; 23: 283–288
- Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.f; Turner, R.C.(1985)**:Homeostasis model assessment - insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. *Diabetologia*; 28:412-419.
- Mayerson, A.B. ; Schieffer, B.; Harp, J.B.; et al. (2002)** :The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. *Diabetes*; 51: 797–802.
- Mc Gill, J.B. and Reilly, P.A. (2001)**: combination treatment with telmisartan and hydrochlorothiazide in lack patient with mild to moderate hypertension .*Clin cardiol*; 104:503-16.
- Miguel, L.; Redson, J. and Schmieder, R. (2007)**: Cardiovascular risk reduction by reversing endothelial dysfunction ARBSc , ACE inhibitors, or both? Expectations from the (ONTARGRT) trial Programme. *Hypertens*; 15:121-123.
- Miura, M.; Satoh, S.; Inoue, K.; Saito, M.; Habuchi, T. and Suzuki, T. (2008)**: Telmisartan pharmacokinetics in japanese renal transplant recipients. *Clinical Chimica Acta*; 399: 83-87.
- Montagnani, M; Golovchenko, I; Kim, I. et al., (2002)**: Inhibition of phosphatidyl inositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. *J Biol Chem*; 277:1794-9.



- Moraes, L.; Piqueras, L.; Bishop-Bailey, D. (2006):** Peroxisome proliferator-activated receptors and inflammation. *Pharmacology & Therapeutics*; 110(3): 371-385.
- Mukoyama, M.; Nakajima, M.; Horiuchi, M.; Sasamura, H.; Pratt, R.E. and Dzau, V.J. (1993):** Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven transmembrane receptors. *J Biol Chem*; 268: 24539-24542.
- Murata, T., Ishibashi, T., Khalil, A., et al. (1995):** Vascular endothelial growth factor plays a role in hyper permeability of diabetic retinal vessels. *Ophthalmic Res*; 27: 48-52.
- Nahmias, C. and Strosberg, D. (1995):** The angiotensin AT receptor: Searching. For signal–transduction pathways and physiological function. *Trends Pharmacol Sci*; 16:233-225.
- Nakai, T.; Satoh, K.; Kosugi, T.; Hoshi, K. and Ichihara, K. (1999):** Participation of angiotensin II and bradykinin in contractile function in dog stunned myocardium. *Eur J Pharmacol*; 15 (3):187-96.
- Nakano, Y.; Tobe, T.; Choi – Miura, N.H.; Mazda, T.; Tomita M. (1996):** Isolation and characterization of GBP28, a novel gelatin – binding protein purified from human plasma. *J Biochem (Tokyo)*; 120 : 803 – 812.
- Nap, A.; Balt, J.C.; Pfaffendorf, M. and Van Zwieten, P.A. (2002):** Sympatholytic properties of several AT₁ receptors an agonists in the isolated rabbit thoracic aorta. *J Hypertens*; 20(9): 1821-8.



- Neutel, J.M., and Smith, D.H.G. (2003):** Dose response and antihypertensive efficacy of the AT₁ receptor antagonist telmisartan in patient with mild to moderate hypertension. *Adv. Ther*; 15: 206-17.
- Neutel, J.M.; Frishman, W.H.; Oparil, S.; Papademitriou, V. and Guthrie, G. (1999):** Comparison of telmisartan with lisinopril in patients with mild-to- moderate hypertension. *Am J Ther*; 6(3): 161-6.
- Neutel, J.M.; Kolloch, R.E.; Plouin, P.F.; Meinicke, T.W.; Schumacher, H.(2003):** Telmisartan vs. losartan plus hydrochlorothiazide in the treatment of mild- to- moderate essential hypertension- a randomized ABPM study. *Hum Hypertens*; 17(8): 569-75.
- Ozono, R.; Wang, Z.Q.; Moore,, A.F.; Inagami, T.; Siragy, H.M. and Carey, R.M. (1997):** Expression of the subtype of angiotensin 2 receptor protein in rat kidney. *Hypertension*; 30: 1238-1246.
- Pagets, G. T. and Barnet, I. M. (1964):** In evaluation of drug activates pharmacometries Eds. Laurence, D.R. and Bacharach, A.L.; 1-135. Academic press, London and New York.
- Pagliassotti, M.J.; Shahrokhi, K.A. and Moscrello, M. (2001):** Involvement of liver and skeletal muscle in sucrose induced insulin resistance : Dose – response studies. *Am J Physiol* 266: R1637 – R1644.
- Park, C.G. and Leenen, F.H. (2001):** Effects of centrally administrated losartan on DOCA-salt hypertensive rats. *J. Korean Med Sei*; 16 :(5):553-557.



- Parker, A.B.; Azevedo, E.R.; Baird, M.C.; Smith, S.J.; Arnold, J.M.; et al., (2000):** Assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. *AM Heart*; 138(5 Pt 1):843-8
- Pascual, G.; Fong, A. L.; Ogawa, S. et al. (2005):** A simulation dependant pathway mediates transrepression of inflammatory response genes by (PPAR)- γ .*Nature* ;437759-63.
- Pershadsihgh H.A. and Kurtz T.W.(2004):** Insulin- sensitizing effects of telmisartan implications for treating insulin- resistant hypertension and cardiovascular disease, *Diabetes Care*, 27:1015.
- Pelliccia, F.; Pasceri, V.; Cianfrocca, C.; Vitale, C.; Speciale, G.; Gaudio, C., Rosano ,G.M. and Mercuro, G. (2010):** Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. *Atherosclerosis*.210(2):510-5.
- Pietrement, C.; Malot, L.; Santerne, B.; Roussel, B.; Motte, J. and Morville, P. (2003):** Neonatal Acute Renal Failure Secondary to Maternal Exposure to Telmisartan, Angiotensin II Receptor Antagonist. *J Perinatol*; 23(3): 254-5.
- Plutzky, J. (2000):** Emerging concepts in metabolic abnormalities associated with coronary artery disease. *Curr Opin Cardiol*; 15:416–421.



- Prasad, A. and Quyyumi, A. (2004):** Renin- angiotensin system and angiotensin receptor blockers in the metabolic syndrome. *Circulation*; 110:1507-12.
- Rajagopalan, S; Kurz, S; Munzel, T.; et al. (1996):** Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. *J Clin Invest*; 97:1916-23.
- Rajala, M.W. and Scherer, P.E. (2003)** The adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis *Endocrinology*; 144: 3765–3773.
- Randle, P.J.; Priestman, D.A. and Mistry, S.C. (1998`):** Glucose fatty acid interactions and the regulation of glucose disposal. *J Cell Biochem*; 55 : 1-11.
- Rangwala, S.M. and Lazar, M.A. (2004) :** Peroxisome proliferator activated receptor gamma in diabetes and metabolism. *Trends Pharmacol Sci*; 25: 331–336.
- Redón, J; Luque- Otero, M; Martell, N.; et al. (2005):** Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan- treated hypertensive patients. *Pharmacogenomics*; 5:14-20.
- Rhee, S.G. and Choi, K.D. (1992):** Regulation of inositol phospholipid-specific phospholipase C isozymes. *J Biol Chem* 267:12393–12396.
- Ricote , M.; Huang, J.; Fajas, L.; et al. (1998):** Expression of the (PPAR)- γ in human atherosclerosis and regulation in



macrophages by colony stimulating factors and oxidized LDL. Proc Natl Acad USA; 95:7614-9.

Robinson, M.J. and Cobb, M.H. (1997): Mitogen-activated protein kinase pathways. Curr Opin Cell Biol; 9:180–186.

Rong, X.; Li, Y.; Ebihara, K.; Zhao, M.; Naowaboot, J.; Kusakabe, T.; Kuwahara, K.; Murray, M.; and Nakao, K.(2010): Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia. (15).

Rosmond, R.(2005): Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology; 30:1–10..

Ruan, H. and Lodish, H.F.(2004): Regulation of insulin sensitivity by adipose tissue derived hormones and inflammatory cytokines. Curr Opin Lipidol; 15:297-302.

Rubins, H.B. Pravenec, M.; Ogihara, F.; et al. (2002) Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high- density lipoprotein intervention trial (VA-HIT). Arch Intern Med;162: 2597–2604.

Ruilope, L. M. and Segura, J. (2003): Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther; 25:3044-64.

Sadoshima, J. and Izumo, S. (1998): The heterotrimeric Gq protein-coupled angiotensin II receptor activates p21 ras via the tyrosine kinase Shc-Grb-Sos pathway in cardiac myocytes. EMBO J; 15: 775-787.



- Safar, M.E.; Levy, B.I. and Struijker-Boudier, H. (2003):** Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular disease. *Circulation*; 107: 2864-9.
- Savage, D.B.; Wassmann, S.; Zolk, O.; et al., (2003):** Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor- γ . *Diabetes*; 52: 910–917.
- Schaefer, A.; Luker, P.W.; Brickel, M.; et al., (2001):** Pharmacokinetic evidence of a lack of interaction between telmisartan and simvastatin. Poster presented at the 4th International Symposium on Angiotensin II Antagonism. London;10: 3-5
- Schupp, M.; Janke, J.; Clasen, R.; Unger, T; and Kintscher, U. (2004):** Angiotensin type I receptor blockers induce peroxisome proliferators- activated receptor- γ activity. *Circulation*; 109: 2054-57.
- Sengul, A.M; Altuntas, Y.; Kurklu, A., et al. (2006):** Beneficial effect of lisinopril plus telmisartan patients with type2 diabetes, microalbuminuria and hypertension. *Diabetes Res Clin Pract*; 71:210-9.
- Sharabi, Y.; Herman, M.; Kamari, Y.; et al.(2007):** Effect of PPAR- γ agonist on adiponectin levels in the metabolic syndrome: lesion from the high fructose fed rat model. *Am J Hypertens*; 20:206-210.
- Sharma, A.M. (2006):** Telmisartan: the ACE or ARBs? *Hypertension*; 47:822-3.



- Sharpe, M.; Jarvis, B. and Goa, K.L. (2001):** Telmisartan: a review of its use in hypertension. *Drugs*; 61 (10): 1501-29.
- Shen, J.; Jiao, Z.; Li, Z.D.; Shi, X.J. and Zhong, M.K. (2005):** HPLC determination of telmisartan in human plasma and its application to a pharmacokinetic study *Pharmazie*; 60(6):418-20.
- Shen, W.; Kohn, T.; Zice, F.; Xian, J.; Sujen, L. and Michael, S. (2008):** Synthesis of benzimidazoles from 1,1-dibromoethenes. Elsevier 49; 7284-7286.
- Shepherd, J.; Cobbe, S.M.; Ford, I.; Isles, C.G.; Lorimer, A.R and Packard C.J. (1995):** Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med*; 333: 1301- 1307.
- Siedel, J.H.; Schlumberger, S.; Klose, J.; Washlefeld, A.W. (1991):** quoted from Boehringer Mannheim GMBH Diagnostic Manual. *Clin Chem Bioch*; 19:838.
- Siragy, H.M. and Carey, R.M. (1997):** The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. *J Clin Invest*; 100:264–269.
- Siragy, H.M.; de Gasparo, M. and Carey, R.M. (2000):** Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. *Hypertension*; 35: 1074-1077.
- Smith, D.H.G.; Matzek, K.M. and Kempthorne-Rawson J. (2000):** Dose response and safety of telmisartan in patients with mild to moderate hypertension. *J Clin Pharmacol*; 40: 1380-90.



- Smith, D. Neutel, J. and Morgenstern, P. (1998):** Once daily telmisartan compared with enalapril in the treatment of hypertension. *Adv Ther*;15: 229-240.
- Sokołowski, M.; Marek, L.; Kowalski, Z. and Pawliczak, R. (2005):** Peroxisome proliferator-activated receptors- γ (PPAR- γ) and their role in immunoregulation and inflammation control. *Postepy Hig Med Dosw*; 59: 472-484.
- Sowers, J.R. (1991):** Is hypertension an insulin resistant state? Metabolic changes associated with hypertension and antihypertensive therapy. *Am Heart J*; 122 : 932 – 5.
- Sowers, J.R. (1999):** Clinical implication of hypertension in diabetic patient. *Am J Hypertension*; 130 : 415 – 424.
- Spác, J.; Soucek, M.; Riháček, I.; Nemcová, H.; Pluháček, L. (2010)** Aortic pulse wave velocity in patients with metabolic syndrome and hypertension treated with sartans. *Vnitr Lek*.56(8):880-3.
- Spears, M.; McSharry, C. and Thomson, N.C. (2006):** Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. *Fundam Clin Pharmacol*; 20(5):429-47.
- Stangier, J.; Hendriks, M; and van Ier J.; et al., (2002):** Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy volunteers. *Journal of Clinical Pharmacology*; 40(12 Pt 1):1331-7.
- Stangier, J.; Su, C.A.P.F. Roth, W. (2000):** Pharmacokinetics of orally and intravenously administered telmisartan in healthy young



and elderly volunteers and in hypertensive patients. *J Int Med Res*; 28 (4): 149-67.

Stangier, C.A.; Su, G. Schondorfer and W. Roth. (2000): Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. *J Clin Pharmacol*; 40: P 1355-1364.

Stangier, J.; Su, C.A.P.F. van Heiningen, P.N.M.; et al. (2001): The inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge *J RAAS*; 2 (1): 83.

Steiner, G. (2002): Treating lipid abnormalities in patients with type 2 diabetes mellitus. *Am J Cardiol*; 88: 37N–40N.

Storlein, L.H.; Kraegen, E.W.; Jenkins, A.B. and Chisholm, D.J. (1998): Effects of sucrose vs. starch diets on in vivo insulin action, thermogenesis & obesity in rats. *Am J Clin Nutr*; 47 : 420 – 7.

Strazzullo, P; and Gallett, F. (2004): Impact of the renin- angiotensin system of lipid and carbohydrate metabolism. *Curr Opin Neph Hypert*; 13:325-32.

Strehlow, K.; Nickenig, G.; Roeling, J.; Knorr, A. and Bohm, M. (1999): AT₁ receptor regulation in salt – sensitive hypertension *Am J Physiol Heart Circ*; 277 : H1701 – H1707.

Strohmenger, H.U; Linder, K. and Wienen, W. et al., (1997): Effects of the AT₁ - selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs. *Resuscitation*; 35:61-68.



- Sugimoto, K.; Qi, N.R.; Kazdova, L.; T.and Kurtz, T.W(2006):** Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension; 47: 1003–1009.
- Tabas, I. (2006):** Consequences and therapeutic implication of macrophage apoptosis in atherosclerosis :The importance of lesion stage and phagocytic efficiency, Arterioscler Thromb Vasc Biol; 25: 2255-64.
- Takano, H. Hasegawa, H. Zou, Y. and Komuro, I. (2004):** Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm; 10:2779-86.
- Takaya, T.; Kawashima, S.; Shinohara, M.; et al., (2006):** Angiotensin II type I receptor telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis;186:402-10
- Takezako, T.; Gogonea, C.; Saad, Y.; Noda, K. and Karnik, S.S. (2004):** Network leaningl as a mechanism of insurmountable antagonism of the AT₁ receptor by non- peptide antagonists. J Biol Chem; (30). 115-119.
- Tenenbaum, A.; Fishman, Z. and Motro, M. (2003):** Metabolic syndrome and type 2 diabetes mellitus : Focus on peroxisome proliferators activated receptor (PPAR).Cardiovascular Diabetology; 2(4): 1475-2840
- Thornburn, A.W.; storlein, L.H.; Jenkins, A.B.; Khouri, s. and Kraegen, E.W.(1989):**Fructose –induced in vivo insulin



resistance and elevated plasma triglyceride levels in rats. *AM J Clin Nutr*; 49:1155-63.

Timmermans, P.B.; Wong, P.C.; Chiu, A.T. and Herblin, W.F. (1991): Nonpeptide angiotensin II receptor antagonists. *Trends Pharmacol Sci*; 12: 55-61.

Togashi, N.; Ura, N.; Higashiura, K.; Murakami, H. and Simamoto, K.(2000): The contribution of skeletal muscle tumor necrosis factor- α to insulin resistance and hypertension in fructose-fed rats. *Hypertens*; 18: 1605-10.

Touyz, R.M. and Schiffrin, E.L. (2000): Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. *Pharmacol; Rev.* 52:639-672.

Touyz, R.M.; El Mabrouk, M. and Schiffrin, E.L. (1999a): MEK inhibition attenuates Ang II-mediated signaling and contraction in SHR vascular smooth muscle cells. *Circ Res*; 84:505–515.

Touyz, R.M.; Endemann, D.; Li, .S. and Schiffrin, E.L. (1999b) :Role of AT₂ receptors in angiotensin II-stimulated contraction of small arteries in young SHR. *Hypertension*; 33(1 pt 2):366–373.

Touyz, R.M.; He, G.; Deng, L. Y. and Schiffrin, E.L. (1999c) :Role of extracellular signal regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance vessels. *Circulation*; 99:392–399.

Tsuzuki, S.; Eguchi, S. and Inagami, T. (1996): Inhibition of cell proliferation and activation of protein tyrosin phosphatase



mediated by angiotensin II type 2 receptor in R3T3 Cells. Biochem Biophys Res Commun; 228: 825-830.

Uchida, H.; Nakamura, Y.; Kaihara, M.; et al., (2004): Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res; 27:545-50.

Ueno, Y., Mohara, O.; Brosnihan, K.B. and Ferrario, C.M.(1988) : Characteristics of hormonal and neurogenic mechanism of deoxycorticosterone-induced hypertension. Hypertension; 11(suppl. 1) : I172 - 177.

Unger, T.(2003) : The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol; 22:91 (10A):28-34.

Ushio-Fukai, M.; Griendling, K.K.; Akers, M.; Lyons, P.R. and Alexander, R.W. (1998): Temporal dispersion of activation of phospholipase C-beta 1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. J Biol Chem; 273:19772–19777.

Venema, R.C.; Ju, H.; Eaton, D.C. and Marrero, M.B. (1998): Angiotensin II-induced association of phospholipase C gamma 1 with the G-protein-coupled AT1 receptor. J Biol Chem; 273:7703–7708.

Vitale, C.; Mercurio, G.; castiglione, C.; et al. (2005): Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol; 4:6.



- Vu-Dac, N.; Schoonjans, K.; Kosykh, V.; Dallongeville, J.; Heyman, R.A. and Staels, B. (1995):** Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. *J Clin Invest* 96: 741–750.
- Vu-Dac, N.; Schoonjans, K.; Laine, B.; Fruchart, J.C., Auwerx, J. and Staels B (1994):** Negative regulation of the human apolipoprotein A-1 promoter by fibrates can be attenuated by interaction of the peroxisome proliferator activated receptor with its response element. *J Biol Chem*; 269 :31012–31018.
- Walgren, M.C.; Young, J.B.; Kaufman, L.N. and Landsberg, L. (1998):** The effects of various carbohydrates on sympathetic activity in the heart & interscapular brown adipose tissue in the rat. *Metabolism*; 36 : 585 - 94
- Watanabe, A. and Endoh, M. (1998):** Relationship between the increase in Ca^{2+} transient and contractile force induced by angiotensin II in aequorin-loaded rabbit ventricular myocardium. *Cardiovasc Res*; 37 (2): 524-31.
- Welch, J.S.; Laine, B.; Ferrario, C.M.; et al. (2003):** PPAR gamma and PPAR delta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. *Proc Natl Acad Sci*; 100: 6712–6717.
- Wienen, W.; Enzeroth, M. and Van Mell, J. (2000):** A review on telmisartan: a novel, long acting angiotensin 11- receptor antagonist. *Cardiovasc Drug Rev*; 18:127-156.



- Wienen, W.; Huel, N.; Van Mell, J.C.; Narr, B.; Ries, U. and Entzeroth, M. (1993):** Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist BIBR 227. *Br J Pharmacol*; 110 (1): 245-52.
- Wienen, W.; Richard, S.; Champeroux, P. and Audeval- Gerard, C. (2000):** Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long- term treatment in hypertensive diabetic rats. *J. Renin Angiotensin Aldosterone Syst*; 2 (1) : 31-6.
- Wood, D.A.; De Backer, G.; Faergem, O.; Graham, J.; Mancini, G. and Pyorala, K. (1999):** Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of the European Society of Cardiology, European Atherosclerosis Society, and European Society of Hypertension. *Eur Heart J*; 19 : 1434 – 1503.
- Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; and Chou, C.J. (2003):** Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest*; 112: 1821–1830.
- Yamada, T.; Akishita, M.; Pollman, M.J.; Gibbons, G.H.; Dzau, V.J. and Horiuchi, M. (1998):** Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: An in vivo gene transfer study. *Life Sci*; 63: 289-295.
- Yamagishi, S. and Nakamura, K. (2006):** Telmisartan , its potential therapeutics implications in cardiometabolic disorders. *Recent Patents Cardiovasc Drug Discov*; 1(1): 79-83.



- Yamagishi, S. and Takeuchi, M. (2005):** Telmisartan is a promising cardiometabolic sartan due to its unique PPAR- γ - inducing property. *Med Hypotheses*; 64:476-8.
- Yamagishi, S.; Amano, S.; Inagaki, Y.; et al., (2003):** Angiotensin II-type1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. *Drugs Ex Clin Res* 29: 75-80.
- Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; et al., (2001):** The fat – derived hormone adiponectin reverses insulin resistance associated with both lipodystrophy and obesity. *Nat Med*; 7 : 941 – 946.
- Yetterberg, H. and Edvinsson, L. (2001):** Characterisation of angiotensin II receptors in isolated human subcutaneous resistance arteries. *J. Renin-angiotensin-Aldosterone system*; 2: S37-S41.
- Yusuf, S. (2002):** From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. *Am J. Cardiol*; 24(2A): 18A-25A.
- Zimmet, P.; Alberti, K.G. and Shaw, J.(2001) :**Global and societal implications of the diabetes epidemic. *Nature* ;414:782–787.